Tags

Type your tag names separated by a space and hit enter

The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma.
Am Rev Respir Dis 1987; 136(2):369-73AR

Abstract

In order to investigate the contribution of histamine to bronchoconstriction provoked by inhaled allergen and adenosine monophosphate (AMP), we have observed the effects of prior treatment with the potent H1-receptor antagonists, terfenadine and astemizole. Nine mild, atopic asthmatics underwent inhalation challenge tests on 6 separate days with histamine, allergen extract, and AMP using single concentrations previously shown to produce a 30% fall in FEV1. For each agonist, bronchoprovocation was performed 3 h after treatment with either terfenadine 180 mg or matched placebo, and airway caliber assessed by measurement of FEV1 over a period of 45 min. AMP challenge was also performed after prior treatment with astemizole. After placebo, histamine produced rapid bronchoconstriction, reaching a maximum within 5 min and returning to within 10% of baseline at 25 min. Pretreatment with terfenadine abolished the bronchoconstrictor response to histamine completely. In contrast, bronchoconstriction provoked by allergen after placebo was slower in onset and sustained during the 45 min of observation. Terfenadine only partially inhibited this response to allergen by 50 +/- 10% (mean +/- SEM) with the maximal effect being observed within the first 5 to 8 min of challenge. AMP inhalation provoked rapid bronchoconstriction similar in time course to that of histamine, and this reaction was inhibited by 86 +/- 8.1% by terfenadine. Astemizole produced inhibition of the response to AMP that was almost identical to that of terfenadine. On the basis of in vitro studies, we interpret these differential effects of terfenadine as reflecting the contribution of histamine to the various airway challenges.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3619195

Citation

Rafferty, P, et al. "The Contribution of Histamine to Immediate Bronchoconstriction Provoked By Inhaled Allergen and Adenosine 5' Monophosphate in Atopic Asthma." The American Review of Respiratory Disease, vol. 136, no. 2, 1987, pp. 369-73.
Rafferty P, Beasley R, Holgate ST. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma. Am Rev Respir Dis. 1987;136(2):369-73.
Rafferty, P., Beasley, R., & Holgate, S. T. (1987). The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma. The American Review of Respiratory Disease, 136(2), pp. 369-73.
Rafferty P, Beasley R, Holgate ST. The Contribution of Histamine to Immediate Bronchoconstriction Provoked By Inhaled Allergen and Adenosine 5' Monophosphate in Atopic Asthma. Am Rev Respir Dis. 1987;136(2):369-73. PubMed PMID: 3619195.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma. AU - Rafferty,P, AU - Beasley,R, AU - Holgate,S T, PY - 1987/8/1/pubmed PY - 1987/8/1/medline PY - 1987/8/1/entrez SP - 369 EP - 73 JF - The American review of respiratory disease JO - Am. Rev. Respir. Dis. VL - 136 IS - 2 N2 - In order to investigate the contribution of histamine to bronchoconstriction provoked by inhaled allergen and adenosine monophosphate (AMP), we have observed the effects of prior treatment with the potent H1-receptor antagonists, terfenadine and astemizole. Nine mild, atopic asthmatics underwent inhalation challenge tests on 6 separate days with histamine, allergen extract, and AMP using single concentrations previously shown to produce a 30% fall in FEV1. For each agonist, bronchoprovocation was performed 3 h after treatment with either terfenadine 180 mg or matched placebo, and airway caliber assessed by measurement of FEV1 over a period of 45 min. AMP challenge was also performed after prior treatment with astemizole. After placebo, histamine produced rapid bronchoconstriction, reaching a maximum within 5 min and returning to within 10% of baseline at 25 min. Pretreatment with terfenadine abolished the bronchoconstrictor response to histamine completely. In contrast, bronchoconstriction provoked by allergen after placebo was slower in onset and sustained during the 45 min of observation. Terfenadine only partially inhibited this response to allergen by 50 +/- 10% (mean +/- SEM) with the maximal effect being observed within the first 5 to 8 min of challenge. AMP inhalation provoked rapid bronchoconstriction similar in time course to that of histamine, and this reaction was inhibited by 86 +/- 8.1% by terfenadine. Astemizole produced inhibition of the response to AMP that was almost identical to that of terfenadine. On the basis of in vitro studies, we interpret these differential effects of terfenadine as reflecting the contribution of histamine to the various airway challenges.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/3619195/The_contribution_of_histamine_to_immediate_bronchoconstriction_provoked_by_inhaled_allergen_and_adenosine_5'_monophosphate_in_atopic_asthma_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm/136.2.369?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -